




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Prevention</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=f2cae575-0831-4309-9bdd-b6f6bc39064d</link>
        <description>Clinical Topic Feed: Prevention</description>
        <language>en</language>

        

                <item>
                    <title>Is ApoB an Appropriate Cost-Effective Marker For Lipid-Lowering Therapy?</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/04/17/16/45/ApoB Appropriate</link>                    <description>Apolipoprotein B (apoB) may be used as a cost-effective marker to improve population health and guide lipid-lowering therapy (LLT) in primary prevention, according to a computer simulation study published April 8 in JAMA.</description>
                    <pubdate>1776445740000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Asia 2026: Sex-Specific Differences in CVD Risk Factors in South Korea</title>
<link>/Latest-in-Cardiology/Articles/2026/04/15/17/13/Sex-Specific-Differences-in-CVD-Risk-Factors-in-South-Korea</link>                    <description>In adults with cardiovascular disease in South Korea, the rates of awareness and treatment of key cardiovascular risk factors were higher in women than in men, but they had lower rates of risk factor control, particularly for hypertension and hypercholesterolemia...</description>
                    <pubdate>1776367320000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>STEP Analysis: BP Trajectories and CV Outcomes in Older Patients</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/04/16/17/02/step-analysis</link>                    <description>In older patients on intensive blood pressure (BP) treatment, the trajectory of BP control was an effective predictor of cardiovascular risk, with a rapid-stable pattern associated with the lowest risk and uncontrolled or unstable patterns associated with the highest risk, according to a post hoc analysis of data from the STEP trial published April 8 in JACC.</description>
                    <pubdate>1776359760000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACCEL Lite: Addressing Cardiovascular-Kidney-Metabolic Syndrome Health</title>
<link>/Latest-in-Cardiology/Articles/2026/04/14/14/19/accel-lite-14apr2026</link>                    <description>In this interview, Alison L. Bailey, MD, FACC and&#226;€&#175; Chiadi E. Ndumele, MD, PhD discuss Addressing Cardiovascular-Kidney-Metabolic Syndrome Health.</description>
                    <pubdate>1776178140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Top Takeaways from ACC.26</title>
<link>/Latest-in-Cardiology/Articles/2026/04/08/13/19/eagles-eye-view-08apr2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30.</description>
                    <pubdate>1775654580000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Biological Sex, Gender, and Vascular Disease: Bridging the Gap to Precision Care in Women</title>
<link>/Latest-in-Cardiology/Articles/2026/04/07/11/57/Biological-Sex-Gender-and-Vascular-Disease</link>                    <description>Biological sex and gender have a great influence on health, disease presentation, and clinical outcomes. Historically, medical research and clinical practice have treated the male body as the standard, often viewing female physiology and symptoms as deviations, except in reproductive health.</description>
                    <pubdate>1775576760000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Revolutionizing Vascular Medicine: The Transformative Role of Artificial Intelligence in Diagnosis, Management, and Outcomes</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/16/10/Revolutionizing-Vascular-Medicine</link>                    <description>Artificial intelligence (AI) is rapidly reshaping how clinicians approach vascular disease, offering sophisticated tools that enhance diagnostic accuracy, enable earlier disease detection, and improve risk stratification across the spectrum of peripheral artery disease (PAD), pulmonary embolism (PE), carotid artery disease, and aortic disease.</description>
                    <pubdate>1775124120000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Editors&#39; Corner | Proven, Practical, Patient First: Turning Research Into Results</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/01/Editors-Corner-Proven-Practical-Patient-First</link>                    <description>This issue brings together a set of stories united by a central theme familiar to every cardiologist: how high&#226;€‘quality evidence becomes high&#226;€‘value care. From prevention in childhood to advanced interventions for complex disease, each story in these pages reflects a different point along the continuum of heart health &#226;€“ yet all focus on turning research into meaningful, practical action.</description>
                    <pubdate>1775046000000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Cover Story | Renal Denervation: From Controversy to Comeback in Hypertension Care</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/01/Cover-Story-Renal-Denervation</link>                    <description>Few therapies in cardiovascular medicine have traveled a path as turbulent as renal denervation. Once hailed as a breakthrough for uncontrolled hypertension, the field was abruptly shaken by neutral findings from SYMPLICITY HTN-3.</description>
                    <pubdate>1775045940000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Feature | Moving Upstream: Why the Next Frontier of CV Prevention Begins in Childhood</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/01/Feature-Moving-Upstream</link>                    <description>For years, efforts to address cardiovascular disease have focused primarily on pharmaceuticals and medical procedures &#226;€“ statins, antihypertensives, catheterizations, stents and other devices.</description>
                    <pubdate>1775045880000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>